title: Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.
abstract: Epigenetic regulation of gene transcription by small molecule inhibitors of histone deacetylases (HDAC) is a novel cancer therapy. Vorinostat (Zolinza()) is the first FDA approved HDAC-inhibitor for treatment of patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in Phase I development. In two Phase II trials, vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 24%-30% in refractory advanced patients with CTCL including large cell transformation and Sézary syndrome (SS). The common side effects of vorinostat, similar in all studies, included gastro-intestinal symptoms, fatigue, and thrombocytopenia and the most common serious events were thrombosis. Vorinostat, in combination with other agents such as radiation therapy and chemotherapy, have shown synergistic or additive effects in a variety of cancers in clinical trials.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
authors.forename: Jenny
authors.initials: J
authors.lastname: Vu
references.citation: Exp Hematol. 2005 Jan;33(1):53-61
references.pmid: 15661398
references.citation: Blood. 2003 Apr 15;101(8):3236-9
references.pmid: 12446442
references.citation: Nat Biotechnol. 2007 Jan;25(1):84-90
references.pmid: 17211407
references.citation: J Clin Invest. 2005 Apr;115(4):798-812
references.pmid: 15841167
references.citation: Leukemia. 2002 Jul;16(7):1331-43
references.pmid: 12094258
references.citation: J Cell Biochem. 2004 May 15;92(2):223-37
references.pmid: 15108350
references.citation: Oncogene. 1999 Nov 25;18(50):7016-25
references.pmid: 10597302
references.citation: Anticancer Res. 2003 Jan-Feb;23(1A):499-503
references.pmid: 12680257
references.citation: Nat Clin Pract Oncol. 2005 Mar;2(3):150-7
references.pmid: 16264908
references.citation: Eur J Haematol. 2006 Jan;76(1):42-50
references.pmid: 16343270
references.citation: N Engl J Med. 2004 May 6;350(19):1978-88
references.pmid: 15128898
references.citation: Arch Dermatol. 2002 Mar;138(3):325-32
references.pmid: 11902983
references.citation: J Cancer Res Clin Oncol. 2005 Jun;131(6):385-94
references.pmid: 15754201
references.citation: Cancer Treat Rev. 2004 Aug;30(5):461-72
references.pmid: 15245778
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7
references.pmid: 9501205
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Leuk Lymphoma. 2004 Sep;45(9):1755-65
references.pmid: 15223633
references.citation: J Am Acad Dermatol. 2004 Apr;50(4):600-7
references.pmid: 15034511
references.citation: Eur J Haematol Suppl. 2005 Jul;(66):150-8
references.pmid: 16007885
references.citation: Blood. 2008 Feb 1;111(3):1060-6
references.pmid: 17962510
references.citation: Dermatology. 2003;206(2):142-7
references.pmid: 12592082
references.citation: Nat Rev Drug Discov. 2006 Sep;5(9):769-84
references.pmid: 16955068
references.citation: BMC Biol. 2006 Aug 02;4:24
references.pmid: 16884538
references.citation: J Clin Invest. 2001 Nov;108(9):1321-30
references.pmid: 11696577
references.citation: Biochem J. 2003 Mar 15;370(Pt 3):737-49
references.pmid: 12429021
references.citation: Hematol Oncol Clin North Am. 1995 Oct;9(5):1117-26
references.pmid: 8522488
references.citation: J Am Acad Dermatol. 2005 Feb;52(2):275-80
references.pmid: 15692473
references.citation: Nat Rev Cancer. 2001 Dec;1(3):194-202
references.pmid: 11902574
references.citation: J Clin Oncol. 2001 Jan 15;19(2):376-88
references.pmid: 11208829
references.citation: J Clin Oncol. 2005 Jun 10;23(17):3923-31
references.pmid: 15897550
references.citation: Annu Rev Biochem. 2004;73:417-35
references.pmid: 15189148
references.citation: Leukemia. 2004 Jul;18(7):1288-95
references.pmid: 15141228
references.citation: Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8
references.pmid: 15637150
references.citation: Int J Cancer. 2006 Jul 1;119(1):221-8
references.pmid: 16450389
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6
references.pmid: 14734806
references.citation: Expert Opin Ther Targets. 2004 Oct;8(5):409-22
references.pmid: 15469392
references.citation: Expert Opin Investig Drugs. 2000 Dec;9(12):2923-34
references.pmid: 11093362
references.citation: Blood. 2004 Jun 15;103(12):4636-43
references.pmid: 14996704
references.citation: Curr Pharm Des. 2004;10(19):2289-98
references.pmid: 15279609
references.citation: Blood. 2005 Jul 15;106(2):454-7
references.pmid: 15811959
references.citation: Blood. 1997 Jan 1;89(1):32-40
references.pmid: 8978274
references.citation: Mol Cancer Ther. 2003 Dec;2(12):1273-84
references.pmid: 14707268
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3921-6
references.pmid: 15001702
references.citation: Expert Opin Investig Drugs. 2005 Dec;14(12):1497-511
references.pmid: 16307490
references.citation: Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
references.pmid: 10954755
references.citation: Int J Dermatol. 2003 Mar;42(3):238-41
references.pmid: 12653924
references.citation: Clin Exp Immunol. 1997 Jan;107 Suppl 1:16-20
references.pmid: 9020930
references.citation: J Mol Biol. 2004 Apr 16;338(1):17-31
references.pmid: 15050820
references.citation: Anticancer Res. 1999 Nov-Dec;19(6B):4999-5005
references.pmid: 10697502
references.citation: JAMA. 1992 Mar 11;267(10):1354-8
references.pmid: 1740857
references.citation: Cell Cycle. 2004 Jun;3(6):779-88
references.pmid: 15153801
references.citation: J Invest Dermatol. 1996 Sep;107(3):373-6
references.pmid: 8751973
references.citation: Br J Dermatol. 2006 Aug;155(2):261-6
references.pmid: 16882161
references.citation: Blood. 2007 Jan 1;109(1):31-9
references.pmid: 16960145
references.citation: Int J Cancer. 2006 Aug 15;119(4):944-54
references.pmid: 16550602
references.citation: Curr Opin Hematol. 2005 Jul;12(4):273-8
references.pmid: 15928483
references.citation: Anticancer Res. 2002 May-Jun;22(3):1497-504
references.pmid: 12168829
references.citation: J Invest Dermatol. 2005 Nov;125(5):1045-52
references.pmid: 16297208
references.citation: Curr Med Chem Anticancer Agents. 2005 Sep;5(5):529-60
references.pmid: 16178777
references.citation: Cancer Res. 2004 Apr 1;64(7):2580-9
references.pmid: 15059915
references.citation: Am J Clin Pathol. 2005 Apr;123(4):510-5
references.pmid: 15743738
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5
references.pmid: 12189205
references.citation: Blood. 2002 Nov 1;100(9):3369-73
references.pmid: 12384439
references.citation: Br J Dermatol. 1995 Jul;133(1):6-12
references.pmid: 7669641
references.citation: J Clin Oncol. 2007 Jul 20;25(21):3109-15
references.pmid: 17577020
references.citation: Int J Oncol. 2004 Dec;25(6):1509-19
references.pmid: 15547685
references.citation: Cancer Res. 2002 Sep 1;62(17):4916-21
references.pmid: 12208741
references.citation: J Eur Acad Dermatol Venereol. 2004 Jul;18(4):397-415
references.pmid: 15196152
references.citation: Cell Cycle. 2005 Apr;4(4):549-51
references.pmid: 15738652
references.citation: J Invest Dermatol. 2005 Apr;124(4):741-50
references.pmid: 15816832
references.citation: Arch Dermatol. 2005 Sep;141(9):1176-8
references.pmid: 16172331
references.citation: Br J Cancer. 2000 Sep;83(6):817-25
references.pmid: 10952788
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5
references.pmid: 15596714
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88
references.pmid: 14506144
references.citation: Br J Dermatol. 1974 Dec;91(6):607-16
references.pmid: 4281316
references.citation: Int J Cancer. 2001 Apr 15;92(2):226-31
references.pmid: 11291050
references.citation: Cancer Res. 2000 Sep 15;60(18):5165-70
references.pmid: 11016644
references.citation: J Clin Oncol. 2006 Jan 1;24(1):166-73
references.pmid: 16330674
references.citation: Blood. 2001 Nov 1;98(9):2865-8
references.pmid: 11675364
references.citation: Arch Dermatol. 2001 May;137(5):581-93
references.pmid: 11346336
references.citation: Blood. 2002 Apr 15;99(8):2929-39
references.pmid: 11929784